Pacritinib Demonstrates Control of Symptoms in Phase III Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Data from PERSIST-1, a phase III trial examining pacritinib for the treatment of myelofibrosis, showed that compared to best available therapy (exclusive of a JAK inhibitor), pacritinib therapy resulted in a significantly higher proportion of patients with spleen volume reduction and control of disease-related symptoms.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login